J30-8

• UNSPSC Description:

  J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases[1].

• Target Antigen:

  JNK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/j30-8.html

• Purity:

  99.90

• Smiles:

  O=C1N/C(S/C1=C2C(NC3=C\2C=C(F)C=C3)=O)=N/C4=CC=CC=C4Cl

• Molecular Weight:

  373.79

• References & Citations:

  [1]Dou X, et al. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases. J Med Chem. 2019 Jul 25;62(14):6645-6664.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported

• CAS Number:

  2366255-71-0